Las Vegas, NV -- (SBWIRE) -- 12/16/2013 -- EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more .EquityObserver.com issues a special report on the following stocks: Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX), Sequenom, Inc. (NASDAQ:SQNM), Baltic Trading Ltd (NYSE:BALT),Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX)
Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) managed to keep its gain at 2.13% on below -normal volume of 594,935.00 shares. The stock settled at $1.92 after floating in a range of $1.83 to $1.98. Its latest price has reached market capitalization of $103.94 million. Its 52-week range has been $0.41to $3.65. Catalyst Pharmaceutical Partners, Inc. operates as development-stage specialty pharmaceutical company. It focuses on the development and commercialization of novel prescription drugs targeting rare (orphan) neuromuscular and neurological diseases and disorders.
For How Long CPRX will fight for Profitability? Read This Trend Analysis report
Sequenom, Inc. (NASDAQ:SQNM) traded up on a volume of 5.45 million, lower than its standard daily volume. Shares have gained 5.45% to $2.13. Over the last twelve months, the stock has lost-55.72% and faced a worst price of $1.65. Sequenom, Inc., a life sciences company, provides genetic analysis solutions in the United States and internationally. It operates through two segments, Molecular Diagnostics and Genetic Analysis.
For How Long SQNM’s Gloss will Attract Investors? Find out via this report
Baltic Trading Ltd (NYSE:BALT) settled 3.30% higher at $5.64 on above-normal volume of 2.41M shares during the last trading day. The stock has its 12-month high at $5.75 and 52-week low price was $2.85. It traded in a range of $5.38 to $5.75 during the last trading day. Baltic Trading Limited engages in shipping business in the dry bulk industry spot market worldwide. The company operates a fleet of dry bulk ships that transport iron ore, coal, grain, steel products, and other dry bulk cargoes. As of September 9, 2013, it owned 11 drybulk vessels, including 2 Capesize, 4 Supramax, and 5 Handysize vessels with a total carrying capacity of approximately 736,000 deadweight tons.
Why Should Investors Buy BALT After the Recent Fall? Just Go Here and Find Out
In the last trading session, Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) was down on low volume, trading at a volume of 281,306.00 versus its average daily volume of 701,727.00 shares. At $103, the stock has attained market capitalization of 267.02 million. Progenics Pharmaceuticals, Inc. engages in the research and development of biotechnology product candidates in the areas of oncology and therapeutics worldwide. The company offers RELISTOR (methylnaltrexone bromide), a subcutaneous injection for the treatment of opioid induced constipation (OIC) in patients with advanced illnesses, such as cancer, as well as for the treatment of OIC in patients with non-cancer pain; and RELISTOR-Oral, which has completed Phase III testing for the treatment of OIC in patients with non-cancer pain. It also provides oncology medicines, including PSMA ADC that is in Phase II testing for treatment of prostate and other cancers; and MIP-1404.
Why Should Investors Buy PGNX After the Recent Fall? Just Go Here and Find Out
About Equity Observer:
Equity Observer delivers intra-day insights into the equities, tech and investment world. The website is a window into what’s going on in the business world and why.
EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more.
The disclaimer is to be read and fully understood before using our site, or joining our email list.
http://www.equityobserver.com/ has a no tolerance spam policy; we will not sell or re-distribute your email to any 3rd party. A If applicable, please also unsubscribe from the newsletter using the link at the bottom of the email if you no longer wish to receive our emails. We only send our newsletters to opt-in members.
PLEASE NOTE WELL: The http://www.equityobserver.com/" rel="nofollow" href="http://www.equityobserver.com/"> http://www.equityobserver.com/>
Employees and contributors are NOT registered as an Investment Adviser in any jurisdiction whatsoever.
Read Full Disclaimerat: http://www.equityobserver.com/
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)